Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine CandidateBusiness Wire • 08/25/22
Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorizationMarket Watch • 08/24/22
Pfizer and BioNTech say data shows COVID vaccine has more than 70% efficacy in small children, and cases now rising in just 7 statesMarket Watch • 08/23/22
Pfizer and BioNTech say COVID vaccine data showed 73.2% efficacy among children aged 6 month to 4 yearsMarket Watch • 08/23/22
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of AgeGlobeNewsWire • 08/23/22
Coronavirus tally: Pfizer and BioNTech formally apply for FDA nod for bivalent COVID booster for people aged 12 and olderMarket Watch • 08/23/22
Pfizer asks FDA to authorize Covid booster shots that target omicron BA.5 for people ages 12 and olderCNBC • 08/22/22
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 VaccineBusiness Wire • 08/22/22
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth BillionsInvestors Business Daily • 08/19/22
Teens' Protection From Pfizer's Covid Shot Fades Weeks After Vaccination—But Shot Still Wards Off Serious Illness, Study FindsForbes • 08/17/22